Microbiome surveys indicate that pharmaceuticals are the top predictor of inter-individual
variations in gut microbial community structure 1 , consistent with in vitro evidence that nonantibiotic (i.e. host-targeted) drugs inhibit gut bacterial growth 2 and are subject to extensive metabolism by the gut microbiome 3, 4 . In oncology, bacterial metabolism has been implicated in both drug efficacy 5, 6 and toxicity 7, 8 ; however, the degree to which bacterial sensitivity and metabolism can be driven by conserved pathways also found in mammalian cells remains poorly understood. Here, we show that anticancer fluoropyrimidine drugs broadly inhibit the growth of Although enormous advances in anticancer drug therapy have been made in the last decade, including the development of targeted therapies and immunotherapy, chemotherapeutic drugs, such as fluoropyrimidines, remain mainstay agents in the treatment of cancer 10 . Multiple lines of evidence support the scientific premise that fluoropyrimidines have extensive interactions with the human gut microbiome that may have downstream consequences for treatment outcomes. The oral fluoropyrimidine capecitabine (CAP), which is extensively metabolized to 5-fluorouracil (5FU), 5-fluorodeoxyuridine (5FdUR), and numerous other metabolites ( Fig. 1a, Extended Data Fig. 1 ), meets the FDA criteria for a "highly variable" drug, with a coefficient of variation >30% in intra-subject pharmacokinetic parameters combined with extensive variation between subjects 11 , which cannot be explained by the known dietary or host genetic risk factors 12, 13 . Adverse reactions to CAP require dose adjustments in ~35% of patients and complete discontinuation of therapy in ~10% of patients; GI side effects are common 14, 15 . Of note, fluoropyrimidines were designed to target conserved pathways essential for gut bacterial growth 16, 17 and recent evidence in rats has shown that these drugs alter the gut microbiota [18] [19] [20] . Consistent with these findings, cross-sectional analyses of the human gut microbiome have linked the use of anticancer drugs (including fluoropyrimidines) to changes in gut microbial community structure and function [21] [22] [23] [24] . There is also evidence that the bacterial metabolism of fluoropyrimidines can have downstream consequences for host physiology; two recent studies in worms linked genetic differences in their bacterial food source (Escherichia coli) to sensitivity to 5FU 6, 25 . Furthermore, the increasing administration of oral 3 fluoropyrimidines increases the potential for interactions with the gut microbiota prior to first pass metabolism and absorption into general circulation.
These observations motivated us to conduct a systematic screen for human gut bacterial sensitivity to three fluoropyrimidine drugs: CAP, 5FU, and 5FdUR ( Fig. 1a) . We selected 47 sequenced and publicly available bacterial strains, spanning the 6 dominant phyla found in the human gut (Supplementary Table 1 ). On average, these bacterial species represent 46.0±19.7% of the gut microbiota 26 . Drug sensitivity was evaluated by determining the minimal inhibitory concentration (MIC) in a rich medium that supported the growth of our entire strain collection ( Supplementary Table 1 ). This screen revealed extensive variation in sensitivity to 5FU and 5FdUR (Fid. 1b), spanning >3 orders of magnitude (min=100 ng/ml; max>1 mg/ml) ( Supplementary Table 1 ). Interestingly, 13 (5FU) and 15 (5FdUR) bacterial strains were resistant to the highest concentration assayed, although 11 (5FU) and 8 (5FdUR) displayed partial growth inhibition (range: 12-92% of the growth control). Variation in sensitivity to 5FU and 5FdUR was significantly correlated (rho=0.475, p-value=0.0008; Extended Data Fig. 2a ), as expected based on their shared substructure ( Fig. 1a ) and downstream metabolites (Extended Data Fig. 1) . Bacterial phylogeny was a poor predictor of drug sensitivity with multiple examples of nearest neighbors with opposite phenotypes; for example, Parabacteroides distasonis (5FU MIC=300 ng/ml) and P. merdae (5FU MIC>1mg/ml). This variation was also apparent when grouping bacteria at higher taxonomic levels (Extended Data Fig. 2b ). Based on this observation, we hypothesized that bacteria may be able to rapidly evolve resistance to fluoropyrimidines. Consistent with this, short-term exposure of bacterial strains to 5FU was sufficient to convert sensitive strains to resistant strains (Extended Data Fig. 2c ).
The bioactivation of CAP to 5FU is generally considered to be uniquely catalyzed by mammalian enzymes expressed in the gastrointestinal tract and liver 27 . Surprisingly, we found that multiple gut bacteria were susceptible to the prodrug CAP ( Fig. 1b ) at physiological concentrations (~14 mg/ml following oral administration) 28 . With the exception of a single strain (Providencia rettgeri) we were able to determine a MIC, which spanned two orders of magnitude (min=0.3 mg/ml; max>10 mg/ml) ( Supplementary Table 1 ). Variation in sensitivity to CAP was significantly associated with 5FdUR sensitivity (rho=0.478, p-value=0.0007), but not 5FU (Extended Data Fig. 2d ), suggesting that the ability for bacteria to import and/or activate this compound does not match the overall sensitivity to fluoropyrimidines.
Next, we sought to gain insight into the mechanism of action of fluoropyrimidines against human gut bacteria. We focused our initial efforts on Escherichia coli, due to its robust genetic tools 29 , high prevalence in the human gut (>50% of individuals) 26 , and intermediate level of sensitivity to 5FU (MIC=62.5 μg/ml), which would allow the identification of factors that increase resistance or sensitivity.
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In mammalian cells, the primary target of fluoropyrimidines is thymidylate synthase 30 , a key enzyme required for DNA, RNA, and protein biosynthesis across domains 31 . A key feature of this mechanism of action is that it is nutrient-dependent; excess uracil rescues drug sensitivity 32 . Bacterial sensitivity to 5FU, 5FdUR, and CAP was dependent on the culture media; E. coli assayed in rich culture media had a significantly higher MIC compared to minimal media (Fig. 2a) . The sensitivity of E. coli to fluoropyrimidines was rescued by uracil in a dose-dependent manner (Fig. 2b) ; supplementation of 10 μg/ml of uracil resulted in a 2500-, 40-, and 16-fold increase in MIC towards 5FU, 5FdUR, and CAP, respectively. These results suggest that uracil rescues growth due to countering the inhibition of pyrimidine metabolism by fluoropyrimidines.
Next, we used RNA-seq to gain a more comprehensive view of the metabolic pathways impacted by fluoropyrimidines. E. coli was grown to mid-exponential phase and then exposed to sub-MIC levels of CAP and 5FU (0.5X MIC in LB media) for 30 min (2.53±0.52 million mRNA reads/sample; Supplementary Table 2 ). Both drugs has a marked impact on bacterial transcription relative to vehicle controls with 947 (5FU) and 663 (CAP) differentially expressed genes 33 (fold-change ³|2|, FDR<0.1;
Extended Data Fig. 3a, b, Supplementary Table 3 ). This represented 21.8% (5FU) and 15.3% (CAP) of genes in the genome. While there was a significant correlation between fold-change in response to 5FU and CAP treatment (R 2 =0.163, p-value<0.0001), (Extended Data Fig. 3c ) only 16.9% of the upregulated genes and 6.6% of the down-regulated genes were consistent between both drugs (Extended Data Fig. 3d ).
Pathway enrichment analysis revealed that among other pathways pyrimidine metabolism was impacted by 5FU (Extended Data Fig. 3e ), while flagellar assembly and primary metabolism pathway were impacted by CAP (Extended Data Fig. 3f ). As seen for the overall transcriptional response, there was a significant correlation between fold-change in response to both drugs for the 46 genes involved in pyrimidine metabolism (R 2 =0.199, p-value=0.0019; Fig. 2c, Supplementary Table 3 ). To test if any of these genes play a causal role in bacterial sensitivity to fluoropyrimidines, we screened bacterial strains deficient for each of the 28 non-essential genes that were differentially expressed in response to either of the two drugs. Surprisingly, these results demonstrated that nearly all of these genes do not impact drug sensitivity, with the exception of upp (uracil phosphoribosyltransferase) ( Supplementary Table 4 ).
Consistent with prior studies 34 , upp-deficient E. coli displayed high-level resistance (2,000-fold increase in 5FU MIC) ( Fig. 2d) ; however, this is the first report to our knowledge that demonstrates that an E. coli upp-deficient strain also display cross-resistance to CAP and 5FdUR (Fig. 2d) . Targeted and whole genome sequencing of our 5FU-resistant mutants (Extended Data Fig. 2d ) revealed multiple unique mutations within the upp genes of E. coli and B. fragilis ( Supplementary Table 5 ). In strains with wildtype upp, we identified mutations within other pyrimidine metabolism genes, including uridine 5 phosphorylase (E. coli), uridylate kinase (E. coli), and thymidine kinase (B. ovatus) ( Supplementary   Table 5 ). Taken together, our results support pyrimidine metabolism as a key target for fluoropyrimidines, while also demonstrating broader impacts of these compounds on pathways for primary metabolism, transport, and flagellar assembly (Extended Data Fig. 3e, 3f) that have yet to be directly implicated in drug sensitivity.
Research on antibiotics has demonstrated the importance of multiple resistance mechanisms, including target modification, bypass pathways, target overproduction, decreased cell penetrance, increased efflux, and enzymatic inactivation 35, 36 . We reasoned that the latter might have the potential to impact treatment outcomes due to decreased drug bioavailability and/or gastrointestinal toxicity 37 . To test if drug resistant bacteria encode enzymes capable of drug inactivation (Fig. 3a) , we screened the top 23 strains (49% of the initial set), corresponding to a 5FU MIC cutoff of 50 μg/ml, using a disk diffusion assay. This concentration is physiologically relevant as indicated by the peak plasma concentration of 5FU achieved during intravenous 5FU chemotherapy 38 . This bioassay screen (Fig. 3b, Extended Data   Fig. 4a ) identified two drug inactivating Proteobacteria: E. coli and Salmonella enterica. LC-QTOF/MS confirmed the depletion of 5FU with quantitative conversion to a single metabolite, dihydrofluorouracil (DHFU) (Fig. 3c) . These results may help to explain why many of the tested E. coli pyrimidine metabolism mutants did not have increased sensitivity or resistance to 5FU, due to the fact that E. coli converts nearly all of the administered drug to DHFU instead of all of the other theoretically possible downstream metabolites of 5FU (Extended Data Fig. 1) . Consistent with this, attempts to detect and quantify peaks for other fluorinated compounds were unsuccessful ( Supplementary Table 6 ); only 5FU and DHFU were detected.
In mammalian cells, dihydropyrimidine dehydrogenase (DPYD) is responsible for the biotransformation of 5FU to DHFU 39 . Patients with DPYD deficiency are linked with high systemic exposure to 5FU and adverse events 39 . In E. coli, DPYD is encoded by two neighboring genes: preT and preA found within the preTA operon 40 . Purified PreTA protein has been shown to be sufficient to catalyze the reduction of the pyrimidines uracil and thymine, as well as 5FU 40 ; however, the genes necessary and sufficient for this activity in bacterial cells remained unknown. We generated a clean deletion of the preTA operon in E. coli MG1655 (ΔpreTA), which resulted in a complete loss-of-function in our bioassay (Extended Data Fig. 4b ) and quantitatively confirmed by LC-QTOF/MS (Fig. 3d) . Chromosomal complementation with a constitutively expressed preTA operon (ΔpreTA/preTA + ) resulted in an increased rate of metabolism relative to wild-type E. coli (Fig. 3d and Extended Data Fig. 4b ). An empty vector control (E. coli ΔpreTA/pINT1) had no impact on either assay. We confirmed the role of the preTA operon in 5FU inactivation with a second strain of E. coli (BW25113) (Fig. 3d, Extended Data Fig. 4c) .
Comparable growth was observed for each isogenic strain in the presence and absence of 5FU, with the 6 exception of ΔpreTA/preTA + , which showed a significant increase in drug tolerance in minimal media ( Fig. 3e) .
These results demonstrate that preTA is both necessary and sufficient for metabolism of 5FU by E. coli, and that high levels of preTA expression ameliorate the observed inhibition of bacterial growth.
Consistent with these results, E. coli MG1655 growth was unaffected by DHFU (MIC>1 mg/ml). We reasoned that the bacterial biotransformation of 5FU by preTA would similarly interfere with the activity of this drug against cancer cells. Cell-free conditioned media from each of our engineered E. coli strains was added to the colorectal cancer cell line HCT-116. Uninoculated media and preTA-deficient conditioned media supplemented with 5FU inhibited cancer cell proliferation; however, this effect was fully rescued by wild-type E. coli and the ΔpreTA/preTA + strains (Fig. 3f) .
Given the conservation between mammalian DPYD and bacterial PreTA we were surprised that only two strains were identified in our screen for 5FU inactivating bacteria. Consistent with our bioassay results, a tBLASTn search querying PreTA against the draft genomes of all 22 of the tested strains only revealed a single pair of genomic loci from S. enterica (84% and 94% full length amino acid identity to PreT and PreA, respectively). To identify other putative metabolizing strains, we built a profile Hidden Markov Model (HMM) and used it to search for orthologs of preT and preA across 9,082 bacterial isolate genomes. To minimize false positives due to the fact that both PreT and PreA are part of large protein families with a range of functions and substrate specificities 41 , we required that the preT and preA orthologs were adjacent in the genome and on the same strand. This analysis revealed 1704 putative preTA operons from 407 species, mainly in Proteobacteria (1509 operons from 292 species) and
Firmicutes (172 operons from 92 species) ( Fig. 4, Supplementary Table 7) . This phylum-level distribution was similar for species with an estimated gut prevalence over 5% (n=23) and for species with a gut prevalence of 1% or lower (n=109) 42 . As expected, preTA was conserved in close relatives of E. coli, including other Escherichia, Salmonella, and Citrobacter. However, we also found operons in more distantly related Betaproteobacteria (e.g., Oxalobacter formigenes) and diverse Firmicutes: Anaerostipes hadrus, Eubacterium hallii, and Lactobacillus reuteri. These results were consistent in an independent analysis of 55,427 metagenome-assembled genomes (MAGs) 43 , resulting in the identification of 74 additional preTA operons, all from human gut MAGs, 89% of which were Firmicutes or Proteobacteria (Extended Data Fig. 5, Supplementary Table 8 ).
We validated five putative preTA orthologs through a combination of whole cell assays and heterologous expression. Incubation of preTA-positive strains confirmed the ability of the Firmicutes species Anaerostipes caccae and Clostridium sporogenes to metabolize 5FU (Fig. 4, Extended Data   Fig. 6 ). Heterologous expression in the E. coli ΔpreTA strain enabled us to validate preTA orthologs detected in the Gammaproteobacterium S. enterica, the Betaproteobacterium O. formigenes, and the 7 Firmicute Lactobacillus reuteri (Fig. 4, Extended Data Fig. 6 ). Together, these results demonstrate that bacterial PreTA can maintain its activity against 5FU despite considerable phylogenetic and primary sequence divergence (66-93% similarity). Finally, we determined the prevalence of each preTA encoding species in the human gut. This analysis identified 4 highly prevalent preTA encoding bacterial species (>90% of the analyzed samples), including the Firmicute A. hadrus and the Proteobacterium E. coli (Fig.   4, Supplementary Table 7 ). An additional 13 isolate genomes and 8 MAGs were identified in >10% of the analyzed samples ( Fig. 4, Extended Data Fig. 6, Supplementary Table 7, 8) . Of note, bacteria that carry the preTA operon have been detected in tumor samples across multiple cancer types 5,44-47 , suggesting that this enzyme may be relevant outside of the gastrointestinal tract.
In conclusion, our results demonstrate how pathways for sensitivity to and metabolism of fluoropyrimidine drugs are conserved across two domains of life. The implications of this are many, suggesting that the mechanistic dissection of drug mechanism of action in bacteria may provide translational insights for host tissues and prompting a broader view of the off-target effects (i.e. toxicity) of therapeutics and the degree to which drug-induced shifts in microbial community structure and function have downstream consequences for drug efficacy or toxicity. Importantly, although our in vitro assays suggest that bacterial drug inactivation in the gastrointestinal tract or even within diseased tissue 5 could interfere with drug efficacy, more work is needed to assess the relative impact of this biotransformation on efficacy versus the dose-limiting gastrointestinal side effects, as previously demonstrated for the anticancer drug irinotecan 8 . These results are also consistent with another recent study 9 , which highlighted the unexpected overlap between host and bacterial drug metabolites. Traditional approaches for studying drug disposition do not distinguish these two alternatives 37 , which may explain the difficulties in predicting fluoropyrimidine toxicity using only human genotypic information. Furthermore, our discovery of diverse 
